[1] XU L, SUN X, MA X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae[J]. Ann Clin Microbiol Antimicrob,2017,16(1):18. doi:  10.1186/s12941-017-0191-3
[2] LEE S, HAN S W, KIM K W, et al. Third-generation cephalosporin resistance of community-onset Escherichia coli and Klebsiella pneumoniae bacteremia in a secondary hospital[J]. Korean J Intern Med,2014,29(1):49-56. doi:  10.3904/kjim.2014.29.1.49
[3] CANI E, MOUSSAVI F, OCHERETYANER E, et al. Carbapenem-resistant Klebsiella pneumoniae vertebral osteomyelitis in a renal transplant recipient treated with ceftazidime-avibactam[J]. Transpl Infect Dis,2018,20(2):e12837. doi:  10.1111/tid.12837
[4] MILLS J P, WILCK M B, WEIKERT B C, et al. Successful treatment of a disseminated infection with extensively drug-resistant Klebsiella pneumoniae in a liver transplant recipient with a fosfomycin-based multidrug regimen[J]. Transpl Infect Dis,2016,18(5):777-781. doi:  10.1111/tid.12578
[5] HANRETTY A M, KAUR I, EVANGELISTA A T, et al. Pharmacokinetics of the meropenem component of meropenem-vaborbactam in the treatment of KPC-producing Klebsiella pneumoniae blood stream infection in a pediatric patient[J]. Pharmacother: J Hum Pharmacol Drug Ther,2018,38(12):e87-e91. doi:  10.1002/phar.2187
[6] DE SANCTIS J, TEIXEIRA L, VAN DUIN D, et al. Complex prosthetic joint infections due to carbapenemase-producing Klebsiella pneumoniae: a unique challenge in the era of untreatable infections[J]. Int J Infect Dis,2014,25:73-78. doi:  10.1016/j.ijid.2014.01.028
[7] RANA M M, STURDEVANT M, PATEL G, et al. Klebsiella necrotizing soft tissue infections in liver transplant recipients: a case series[J]. Transpl Infect Dis,2013,15(4):E157-E163. doi:  10.1111/tid.12103
[8] 王硕, 刘明亮. 氨基糖苷类抗生素治疗重度革兰阴性菌感染方案的优化[J]. 国外医药(抗生素分册), 2013, 34(1):16-20.
[9] TUMBARELLO M, VIALE P, VISCOLI C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy[J]. Clin Infect Dis,2012,55(7):943-950. doi:  10.1093/cid/cis588
[10] CANTÓN R, CANUT A, MOROSINI M I, et al. Breakpoints for carbapenemase-producing Enterobacteriaceae: is the problem solved?[J]. Enferm Infecc Microbiol Clin, 2014, 32(Suppl 4): 33-40.
[11] QURESHI Z A, PATERSON D L, POTOSKI B A, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens[J]. Antimicrob Agents Chemother,2012,56(4):2108-2113. doi:  10.1128/AAC.06268-11
[12] 胡付品, 郭燕, 朱德妹, 等. 2017年CHINET中国细菌耐药性监测[J]. 中国感染与化疗杂志, 2018, 18(3):241-251.
[13] TURNIDGE J. Pharmacodynamics and dosing of aminoglycosides[J]. Infect Dis Clin North Am,2003,17(3):503-528. doi:  10.1016/S0891-5520(03)00057-6
[14] LORENZO M P, HOUSMAN E L, HOUSMAN S T, et al. Once-daily amino glycosides[J]. Am J Health Syst Pharm,2016,73(8):529-530. doi:  10.2146/ajhp150756
[15] CRAIG W A. Optimizing aminoglycoside use[J]. Crit Care Clin,2011,27(1):107-121. doi:  10.1016/j.ccc.2010.11.006
[16] MATSUO H, HAYASHI J, ONO K, et al. Administration of aminoglycosides to hemodialysis patients immediately before dialysis: a new dosing modality[J]. Antimicrob Agents Chemother,1997,41(12):2597-2601. doi:  10.1128/AAC.41.12.2597
[17] O'SHEA S, DUFFULL S, JOHNSON D W. Aminoglycosides in hemodialysis patients: is the current practice of post dialysis dosing appropriate?[J]. Semin Dial, 2009, 22(3): 225-230.
[18] ESCHENAUER G A, LAM S W, MUELLER B A. Dose timing of aminoglycosides in hemodialysis patients: a pharmacology view[J]. Semin Dial,2016,29(3):204-213. doi:  10.1111/sdi.12458
[19] KATO H, HAGIHARA M, HIRAI J, et al. Evaluation of amikacin pharmacokinetics and pharmacodynamics for optimal initial dosing regimen[J]. Drugs R D,2017,17(1):177-187. doi:  10.1007/s40268-016-0165-5
[20] JIANG M, KARASAWA T, STEYGER P S. Aminoglycoside-induced cochleotoxicity: a review[J]. Front Cell Neurosci,2017,11:308.
[21] PASQUALE T R, TAN J S. Nonantimicrobial effects of antibacterial agents[J]. Clin Infect Dis,2005,40(1):127-135. doi:  10.1086/426545